Unlikely allies MSD, Cipla link to co-market Isentress in India

MSD (as Merck & Co is known outside the US and Canada) and Cipla, never really considered natural allies, have now formed an India-specific partnership, under which Cipla will co-market the US firm's HIV drug Isentress (raltegravir).

MSD (as Merck & Co is known outside the US and Canada) and Cipla, never really considered natural allies, have now formed an India-specific partnership, under which Cipla will co-market the US firm's HIV drug Isentress (raltegravir).

The deal perhaps unveils a new plank in Cipla's access strategy – an effort to ally with large innovator firms...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category